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Abstract 
Primary brain tumours are heterogeneous regarding histology, genetics, and outcome. Although the 
World Health Organization (WHO) Classification of Tumors of the Central Nervous System has 
greatly aided in standardizing diagnostic criteria throughout the world, it does not yet consider the 
tremendous progress made recently in the molecular classification of many brain tumours. Recent 
practice-changing academic clinical trials have defined a role for routine assessment of MGMT 
promoter methylation in glioblastoma of the elderly and 1p/19q co-deletions in anaplastic 
oligodendroglial tumours. Moreover, large scale molecular profiling approaches have identified new 
mutations in gliomas, affecting isocitrate dehydrogenases (IDH) 1 and 2, H3F3, ATRX and CIC, and 
allowed to subclassify gliomas into distinct molecular subgroups with characteristic features of age, 
localization, and outcome, although they do not yet predict benefit from therapeutic interventions. 
Similarly, transcriptome-based classification of medulloblastoma has delineated four variants that may 
now be candidate diseases to explore novel targeted agents. 
 
Search Strategy and Selection Criteria section 
References for this review were identified through searches of PubMed with the search terms „brain 
tumo(u)r”, “glioma”, “medulloblastoma”, “meningioma”, “ependymoma”, “molecular”, “predictive”, 
and “prognostic” in various combinations, from 2000 to January 2013. Articles were also identified 
through searches of the authors` own files. Only papers in English were reviewed. Data available only 
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in Abstract form were not included. The final reference list was generated on the basis of originality 
and relevance to the broad scope of this review. 
 
Introduction 
 
The World Health Organization (WHO) Classification of Tumours of the Central Nervous System 
distinguishes tumours by histological criteria and, based on morphological features of anaplasia, 
additionally allocates a malignancy grade ranging from WHO grade I to IV to each tumour, if 
applicable. Traditionally the nomenclature of brain tumours is often assigned based on a presumed cell 
of origin which is mainly deduced from cytological similarities of the tumour cells with the various 
normal cell types occuring in the central nervous system and its coverings (Webappendix).1 
From a historical perspective, histopathology thus was the first tool to distinguish brain tumors of 
different grades of malignancy and (presumed) different histogenetic origin, with the overall goal to 
provide clinicians with prognostic information. Histopathological classification alone has its 
limitations, but is greatly aided by immunohistochemical markers that help to discriminate different 
tumour entities with higher certainty, thereby reducing interobserver variability, and allow for a better 
characterization of novel tumour entities and variants. A next level of complexity is added by 
including molecular markers that carry both diagnostic and prognostic information in tumours with 
histologically similar appearance. Nevertheless, molecular markers have become an integral part of 
tumour grading and anatomo-pathological assessment in modern neuro-oncology practice because 
they provide useful information beyond the WHO classification, and molecular marker status now 
guides clinical decision making at least in subtypes of gliomas.2 In parallel, several genome- or 
transcriptome-wide molecular approaches of brain tumour classification indicate that single marker 
profiling may only be a transient diagnostic standard which may soon be replaced at reasonable cost 
by tumour genome-wide molecular profiling techniques, including array-based methods as well as 
diagnostic next generation sequencing. The purpose of this review is to highlight recent advances in 
the molecular diagnosis and classification of primary brain tumours and to discuss how these advances 
inform therapeutic decisions. 
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Gliomas: single marker approaches 
 
IDH mutation 
Isocitrate dehydrogenase (IDH) mutations, 1p/19q co-deletions, and O6-methylguanine DNA 
methyltransferase (MGMT) promoter methylation are the three molecular markers that are currently 
assessed routinely in many brain tumour centres because of their diagnostic, prognostic, or predictive 
value (Table). IDH mutations are early lesions in the development of gliomas and cluster in the active 
site of theses enzymes at codons 132 of the IDH1 respectively 172 of the IDH2 gene. The selective, 
heterozygous mutational targeting of specific sites of either gene seems necessary and sufficient for 
neoplastic transformation, suggesting that these mutations confer a gain of function and do not simply 
affect wildtype IDH function. They favour a neomorphic reaction catalysing the conversion of α-
ketoglutarate into D-2-hydroxyglutarate, a candidate oncometabolite accumulating to high 
concentrations possibly measurable by MR spectroscopy in situ3 and mediating the oncogenic activity 
of IDH mutations.4 Most interestingly, IDH mutations have been reported to be causally linked to 
profound epigenetic changes, mediated by high concentrations of 2-hydroxyglutarate that inhibit 
α−ketoglutarate-dependent epigenetic modifiers such as tet methylcytosine dioxygenase (TET) 2, 
resulting in a glioma CpG island methylator phenotype (G-CIMP).5 In addition, 2-hydroxyglutarate 
stimulates hypoxia-inducible factor (HIF) prolyl 4-hydroxylases (EGLN1. 2 and 3) which in turn leads 
to diminished HIF levels and enhances proliferation as well as soft agar growth of human astrocytes.6 
These insights provided evidence that gliomas with IDH mutations have a distinct pathogenetic origin.  
Hence, the primary molecular approach to classify gliomas of adulthood is to separate gliomas into 
IDH-wildtype versus IDH-mutant gliomas. Among the IDH-wildtype gliomas, there are distinct 
entities such as the grade I pilocytic astrocytomas and primary glioblastomas which originate via 
pathways of tumourigenesis that are independent of the IDH pathway and presumably G-CIMP. 
Conversely, most grade II, grade III and few grade IV gliomas (=secondary glioblastomas) share IDH 
mutations and carry a better prognosis compared to IDH-wildtype gliomas of the same histological 
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grade. In fact, the IDH status was a better discriminator of outcome than histological grade in a pooled 
analysis of 382 WHO grade III and IV gliomas, excluding oligodendroglial tumours.7 The prognostic 
effect of the IDH mutation in patients with WHO grade II gliomas appears to be less strong when 
these patients are not treated with RT or chemotherapy.8 In fact, IDH-wildtype grade II and III gliomas 
remain poorly characterized groups of tumours that seem to have a less favourable prognosis. 
Accordingly, the IDH status should be incorporated into future brain tumour classifications, especially 
since the IDH-mutant tumours are driven by specific epigenetic alterations, phenotypically 
characterized as G-CIMP-positive, a status that may be suitable for specific therapeutic interventions 
that likely will not be successful on an IDH-wildtype (G-CIMP-negative) background. For the future 
development of clinical trials, stratification and separate treatment strategies need to be defined for 
these distinct subgroups. Pooling IDH-mutant and IDH-wildtype tumours in the same clinical trials 
simply because the tumours look alike and are assigned the same histological grade of malignancy is 
not appropriate anymore. 
The IDH status is of undisputed diagnostic value, in particular in positively identifying diffuse gliomas 
and distinguishing them from reactive gliosis as well as various other tumour entities that constitute 
important histological differential diagnoses but are IDH-wildtype lesions. However, the IDH status 
has no defined role in clinical decision making yet within a given tumour entity. 
 
1p/19q co-deletion 
Combined losses of chromosomal arms 1p and 19q resulting from an unbalanced t(1;19)(q10;p10) 
translocation lead to the loss of one hybrid chromosome and thus loss of heterozygosity.9 This 
cytogenetic aberration is strongly associated with oligodendroglial histology and rarely found in other 
tumours. The molecular pathway of oncogenesis associated with this lesion is currently being 
elucidated: most 1p/19q-co-deleted oligodendrogliomas carry mutations in the CIC gene, a homolog 
of the Drosophila gene capicua, on chromosomal band 19q13.210,11 while CIC mutations appear to be 
less common in 1p/19q-co-deleted oligoastrocytomas.12 Less frequently there are mutations in the 
FUBP1 gene, which encodes the “far upstream element-binding protein”, on chromosomal arm 1p.10,11 
1p/19q-co-deleted tumours have long been known to carry a better prognosis than histologically 
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indistinguishable tumours of the same grade of malignancy. While it remains controversial whether 
1p/19q-co-deleted tumours have a less aggressive natural course, it is well established that they are 
more sensitive to radiotherapy (RT) or alkylating agent chemotherapy. Long-term results of two large 
randomized clinical trials – European Organisation for Research and Treatment of Cancer (EORTC) 
26951 and Radiation Therapy Oncology Group (RTOG) 9402 – that explored the value of 
polychemotherapy using procarbacine, lomustin (CCNU) and vincristine (PCV) either prior to or 
immediately after RT indicate that the inclusion of chemotherapy in the first-line treatment confers a 
survival advantage which becomes evident after follow-up of more than six years rather specifically in 
the subgroup of patients with 1p/19q-co-deleted tumours (Table 2). Thus, 1p/19q co-deletions have 
also predictive value for benefit from chemotherapy, in addition to the characterization of a 
prognostically more favourable subgroup.13,14  
The results from these studies led to the suspension of enrolment in the 3-arm CODEL trial which 
aimed at comparing RT plus temozolomide (TMZ) followed by TMZ (RT/TMZ →TMZ) with RT 
alone and TMZ alone. This is because RT alone was no longer considered an appropriate treatment for 
these patients. It has, however, to be noted that these results stem from retrospective analyses and are 
thus explorative, moreover, it remains unclear how many of the long-term survivors treated with RT 
plus PCV experience preserved cognitive function and quality of life. Finally, there is controversy 
whether the same improvement in overall survival could have been achieved with the combination of 
RT and TMZ or even with alkylating agent chemotherapy alone. The German NOA-04 trial which 
compared RT and TMZ or PCV alone15 does not yet provide a conclusive answer regarding 
differences in long-term disease control with PCV versus TMZ since follow-up was too short at the 
time of initial publication. Yet, future clinical trials should probably include RT plus PCV 
polychemotherapy as a control arm. 
MGMT promoter methylation 
The DNA repair protein MGMT repairs the chemotherapy-induced alkylation at the O6-position of 
guanine, the critical mediator of alkylating agent cytotoxicity, and thus counteracts the effects of 
alkylating chemotherapeutic agents such as nitrosoureas or TMZ. Decreased MGMT protein levels are 
predicted to result in decreased ability of repair and therefore should be associated with improved 
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outcome. Hypermethylation of the MGMT gene promoter may lead to silencing of the gene and thus 
decreased protein levels. Numerous clinical trials and cohort studies have shown that MGMT promoter 
methylation is associated with prolonged progression-free and overall survival in glioblastoma patients 
treated with alkylating agent chemotherapy.16-22 In the pivotal trial establishing TMZ chemotherapy 
during and after radiotherapy in newly diagnosed glioblastoma,23 the benefit from chemotherapy was 
almost exclusively attributable to patients with a methylated MGMT gene promoter.18,21 In 2012, two 
independent randomized trials conducted in elderly patients with anaplastic astrocytoma24 or 
glioblastoma24,25 reported a comparison of RT alone versus TMZ chemotherapy alone as initial 
treatment. Subgroup analyses of both trials demonstrated a superior outcome for chemotherapy in 
patients with MGMT promoter-methylated tumours, but an inferior survival in patients with 
unmethylated tumours. These results strongly suggest that treatment strategy should be individualised 
depending on the MGMT status when selecting the appropriate treatment for elderly glioblastoma 
patients who are not commonly treated with combined modality treatment (RT/TMZ→TMZ).  
While MGMT determination by immunohistochemistry shows a marked interobserver heterogeneity 
and does not reliably correlate with promoter methylation or outcome, molecular determination of 
epigenetic activation status most commonly performed by methylation-specific PCR – or 
pyrosequencing of bisulfite-modified DNA - has been established as a reliable method. A thorough 
discussion of the challenges, pitfalls and limitations of MGMT promoter methylation analyses has 
been provided elsewhere.22 Regarding future developments, it is tempting to speculate that the 
National Cancer Institute of Canada (NCIC)/EORTC Intergroup trial exploring hypofractionated RT 
versus hypofractionated RT/TMZ→TMZ may show a survival signal only in patients with MGMT 
promoter-methylated tumours. None of the trials will answer the question whether patients with 
MGMT promoter-methylated tumours may be managed with TMZ alone or might still fare better with 
RT/TMZ→TMZ. 
Anaplastic gliomas, as opposed to the vast majority of primary glioblastomas, show distinct genetic 
and epigenetic aberration profiles implicating different pathomechanisms of tumourigenesis and 
progression. Somewhat unexpectedly, but at second thought not surprisingly, a specific predictive 
value of MGMT promoter methylation was not observed in two anaplastic glioma trials where patients 
 8 
were treated with RT versus alkylating chemotherapy alone15 or with RT versus RT plus alkylating 
chemotherapy.26 Nevertheless, a strong prognostic value of MGMT promoter methylation was 
demonstrated independent of the choice of initial therapy. While it was interesting to observe such a 
striking difference between anaplastic glioma and glioblastoma regarding the predictive role of MGMT 
promoter methylation, the biological basis of this phenomenon remains to be elucidated.  
 
Interaction of various molecular markers 
The three molecular markers described above are not entirely independent. For instance, IDH-mutant 
tumours commonly show MGMT promoter methylation, and 1p/19q-co-deleted tumours typically 
harbour IDH mutations.15,27 IDH-mutant/CIMP-positive anaplastic gliomas almost always have the 
MGMT promoter methylated, while the rate of MGMT promoter methylation in G-CIMP-negative 
tumours was 40-50%, similar to primary glioblastoma. Hence, in most anaplastic gliomas, MGMT 
promoter methylation is part of the G-CIMP phenotype while G-CIMP is rare in primary 
glioblastoma.28 An exploratory analysis of the NOA-04 trial and validation cohorts from NOA-08 and 
the German Glioma Network indicated that a methylated MGMT promoter status is associated with 
superior outcome with chemotherapy with or without RT in the absence, but not in the presence, of 
IDH mutations.29 Thus, MGMT promoter methylation may reflect the G-CIMP phenotype of IDH-
mutant tumours, but may have a different, not yet understood genesis and role in IDH-wildtype 
tumours. Conversely, in a large group of anaplastic glioma patients the epigenetic inactivation of some 
CIMP-associated genes may sensitize the tumours to RT, and potentially chemotherapy, too, 
confounding the MGMT-related effect. It will be of utmost importance to uncover the identity of such 
genes and elucidate their biological implications for this phenomenon since they may facilitate the 
design of new treatment strategies. 
 
Changing treatment paradigms based on biomarker assessment 
Figures 1 and 2 summarize how the assessment of IDH, 1p/19q and MGMT status may be built into a 
management algorithm for patients with anaplastic gliomas and glioblastoma. Such algorithms are 
subject to change as new data and concepts emerge and may need to be adapted to institutional 
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preferences. Importantly, the decision for specific treatments must take into account several issues 
such as patient preference, tumour location, volume of radiotherapy and potential comorbidities that 
might increase the risk of toxicity from chemotherapy. Figure 2 does not address the possible role of 
bevacizumab or other experimental treatments currently explored in the treatment of newly diagnosed 
glioblastoma. 
 
ATRX mutations 
The first evidence for a role of α-thalassemia/mental-retardation-syndrome-X-linked (ATRX) 
mutations in gliomas of various grades of malignancy was their association with alternative 
lengthening of telomeres.30 It was then shown that ATRX mutations are associated with mutations of 
the TP53 and IDH1 genes across glioma entities.11,31 Most importantly, however, these same studies 
established ATRX mutations to be a very specific marker for astrocytic lineage tumours, including 
diffuse and anaplastic astrocytomas as well as a subset of oligoastrocytomas, positioning them as an 
attractive counterpart for 1p/19q co-deletions which appear to be mutually exclusive with ATRX 
mutations. Since the vast majority of mutations detected to date are truncating and thus lead to a 
reduction of protein levels, immunohistochemical demonstration of loss of ATRX may be a reasonable 
surrogate marker of ATRX mutations. Combining 1p/19q and ATRX assessments in a clinical setting 
may thus help in the future to guide the diagnosis within the spectrum of IDH-mutant gliomas and 
eventually to stratify patients for specific treatments. 
 
H3F3A mutation  
Employing exome-wide sequencing of pediatric glioblastomas and pontine gliomas, two recent studies 
identified frequent mutations in the histone H.3.3 gene (H3F3A).32,33 These mutations cluster at two 
critical amino acid residues, namely K27 and G34. Interestingly, the two H3F3A mutations appear to 
define distinct epigenetic subgroups of glioblastoma, with H3F3A (G34) mutant tumours showing 
global DNA hypomethylation.34 Moreover, H3F3A mutations are mutually exclusive with IDH1 
mutations, with each H3F3A mutation type giving rise to tumours located in separate anatomic 
compartments and showing differential expression of the transcription factors OLIG1, OLIG2, and 
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FOXG1.34 This suggests that pediatric glioblastomas with H3F3A K27 or G34 mutations likely arise 
from distinct cellular origins. Moreover, preliminary clinical correlations suggest that these mutations 
are associated with distinct clinical outcome, i.e. patients with H3F3A K27-mutant tumours appear to 
show a particularly poor outcome. From a molecular diagnostic point of view, the demonstration of 
H3F3A mutation, e.g., by DNA pyrosequencing, may help to identify different types of pediatric 
glioblastoma and distinguish these from other gliomas, including pilocytic astrocytoma. More recent 
data indicate mutations in another gene involved in the regulation of histone methylation in 
approximately 15% of pediatric and 8% of adult high-grade gliomas, mostly glioblastomas, namely 
SETD2. These mutations were mutually exclusive with H3F3A mutations but overlapped in part with 
IDH1 mutations in glioblastomas.35 Collectively, all of these mutations (H3.3G34R/V and SETD2, and 
H3.3K27M) are believed to directly alter centrally important histone marks such as H3K36 
trimethylation and H3.3K27 trimethylation, respectively. 
 
EGFRvIII rearrangement 
Approximately 25-30% of primary glioblastomas harbour a characteristic deletion mutant of the 
epidermal growth factor receptor (EGFR) gene referred to as EGFRvIII which results in constitutive 
and ligand-independent receptor activity and is considered an important oncogenic mutation. Its 
prognostic relevance remains controversial, but long-term survival may be inferior in patients whose 
tumours carry this mutation. EGFR-targeted approaches have not been effective in glioblastoma.36 
However, the EGFRvIII mutation also creates a new epitope which is immunogenic and thus a 
candidate tumour antigen in EGFRvIII-positive glioblastoma. Accordingly, vaccination strategies 
based on this unique peptide sequence have been developed and yielded promising overall survival 
results in various phase II trials which also provided preliminary evidence for target antigen 
elimination in recurrent tumours and a link between immune response to the vaccine and outcome.37,38 
A placebo-controlled phase III trial, ACT IV, exploring the efficacy of the EGFRvIII-directed vaccine 
is currently enrolling patients. Finally, EGFRvIII mRNA has also been detected in microvesicles in the 
serum of patients with EGFRvIII-positive glioblastoma,39,40 indicating that it may serve as a biomarker 
to monitor response to therapy and detect relapse. 
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BRAF fusion or point mutation 
Tandem duplications of BRAF at 7q34 resulting in KIAA1549:BRAF gene fusions, or sometimes 
alternative fusion partners, have been recognized as hallmark genetic lesions in pilocytic astrocytoma, 
with a particularly high incidence in cerebellar pilocytic astrocytomas.41,42 These fusions are only very 
rarely found in other tumours. KIAA1549:BRAF gene fusions are therefore considered a very 
important diagnostic aid to distinguish pilocytic astrocytoma from higher grade astrocytic tumours, a 
distinction that can be both challenging and therapeutically highly relevant given the fact that pilocytic 
astrocytomas and glioblastomas share the morphological feature of microvascular proliferation. Other 
genetic alterations of BRAF including point mutations, in particular the activating BRAFV600E missense 
mutation, have also been observed in low-grade gliomas as well as grade III/IV gliomas.43,44 
BRAFV600E mutations are particularly common in pleomorphic xanthoastrocytomas, with two thirds of 
these tumours showing this aberration, which is nowadays easily demonstrated by 
immunohistochemistry using a mutation-specific antibody.45 The glioma-associated BRAF alterations 
all exert their oncogenic activity by activating the mitogen-activated protein kinase (MAPK) 
pathway.42 More recent studies employing large scale sequencing identified an oncogenic hit in the 
MAPK pathway in (almost) all pilocytic astrocytomas (Pfister, unpublished) while they did not reveal 
any significantly mutated gene outside of this pathway, indicating that this tumour may indeed be a 
single-pathway disease. The availability of small-molecule BRAF kinase inhibitors such as 
vemurafenib (PLX4032), which specifically targets BRAFV600E-mutant tumours, provides a new 
therapeutic approach to these subgroups of gliomas and preliminary clinical evidence (Pfister, 
unpublished) suggests that the presence of a BRAFV600E mutation may indeed serve as a potent 
predictive marker for this subset of patients across gliomas of various grades. 
 
Gliomas: unbiased (high throughput) molecular diagnostic approaches 
The notion that high throughput approaches of classifying brain tumours including gliomas are at least 
a valuable addition, if not superior to histopathological grading has been repeatedly supported in large 
datasets. However, due to the complexity in data analysis and interpretation, such techniques have not 
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been introduced into clinical practice (yet). One of the first approaches was to define gene expression 
signatures derived from classical tumour samples and to use these as an aid to diagnose tumour 
samples that were less easily assigned to a specific diagnostic entity by histology alone.46 Gene 
expression profiling of 276 gliomas resulted in the definition of 7 subgroups that did not simply reflect 
the histological diagnoses, but were prognostic, and correlated better with survival than histology. In 
fact, unsupervised bioinformatic clustering added to the prognostic information provided by histology 
whereas histology did not add to the information obtained by gene expression profiling.47 The same 
approach was also applied to patients enrolled in EORTC 2695113 and confirmed the prognostic value, 
moreover, it also allowed to identify a subgroup of patients who specifically benefitted from PCV 
chemotherapy. Superiority of gene expression profiling over 1p/19q testing, however, in predicting 
outcome was not demonstrated.48 Gene expression profiling was also used to identify genes associated 
with outcome and let to the identification of candidate genes such as osteonectin, doublecortin, 
semaphorin 3B49 or FABP7.50 In a subpopulation of 80 glioblastomas from the EORTC/NCIC trial,23 
an expression signature dominated by HOX genes was associated with poor survival in patients treated 
with concomitant chemoradiotherapy, and both the HOX signature and EGFR expression were 
independent negative prognostic factors on multivariate analysis.51 The poor prognostic value of the 
HOX gene-dominated stem cell related self-renewal signature was validated in an independent dataset 
of the same study. The functional association of the HOX gene signature with glioblastoma stem cells 
has been further substantiated and the negative prognostic effect was confirmed.52 
In 2006, Phillips and colleagues proposed a new classification of glioblastomas based on supervised 
gene expression profiling guided by patient outcome and coined the terms of proneural, proliferative 
and mesenchymal glioblastoma subtypes.53 Proneural tumours were often anaplastic gliomas, lacked 
phosphatase and tensin homolog on chromosome ten (PTEN) or EGFR alterations, but exhibited 
Notch pathway activation, and had a better outcome. The distinction of proliferative versus 
mesenchymal was less clear, but made on the basis of expression profiles favouring either 
proliferation or angiogenesis. Extending such analyses, a nine gene set was derived from 4 different 
data sets which provided independent prognostic information after adjusting for clinical factors and 
MGMT promoter methylation.54 
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Two very influential high throughput studies at the genomic level were published in 2008: first, The 
Cancer Genome Atlas (TCGA) project demonstrated genetic alterations in three major signalling 
pathways in the majority of glioblastomas: receptor tyrosine kinase (RTK) / RAS / phosphoinositide-3 
kinase (88%), p53 (87%) and retinoblastoma protein (78%),55 then, IDH mutations were discovered in 
a minority of glioblastoma patients which were young and had a good outcome, consistent with a 
secondary glioblastoma phenotype.56 In 2010, a refined expression-based classification suggested the 
existence of four glioma subtypes: proneural, neural, classical and mesenchymal.57 Gene expression 
patterns in these subgroups showed distinct correlations with those of oligodendrocytes, astrocytes, 
and neurons, providing possible clues to putative lineages of tumour origin. The authors also proposed 
differential benefit from therapy by subgroup, but these data need to be interpreted with caution, given 
the retrospective nature of this analysis and the heterogeneous treatments. Interestingly, annotation of 
the data set with the MGMT promoter methylation status revealed that none of the four subgroups 
displayed an association with the MGMT status.28 Genome-wide DNA methylation profiling provided 
complementary information and most importantly uncovered the G-CIMP phenotype associated with 
IDH1 mutations. Interestingly, IDH-mutant and G-CIMP-positive tumours turned out to be a subgroup 
of the proneural subtype.58 This discovery was instrumental for uncovering the mechanistic link 
between IDH mutations and genome-wide aberration of DNA methylation.5 As detailed above, 
mutations in the histone H3 gene (H3F3A) were detected in more than a third of pediatric 
glioblastomas and more than two thirds of diffuse intrinsic pontine gliomas, further supporting the role 
of epigenetic deregulation in gliomagenesis.31-34 Accordingly, using Illumina 450K array-based 
methylation profiling, a novel subclassification of glioblastoma into 6 subgroups was proposed across 
age groups: the first three are linked to mutations of IDH or codons 27 or 34 of histone H3, which are 
mutually exclusive, the other groups were labelled receptor tyrosine kinase (RTK) I/PDGFRA, 
mesenchymal, and RTKII/classic. These six subclasses exhibited distinct profiles of age distribution, 
tumour localization, and outcome.34 Importantly, this subclassification allowed to further split the 
proneural expression subgroups into basically four subgroups: IDH-mutant, H3F3A (K27)-mutant, 
H3F3A (G34)-mutant, and RTKI/PDGFRA. This is important since only the IDH group of proneural 
glioblastomas remains to be associated with a favourable prognosis, whereas the remaining patients do 
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as poorly as or even worse than patients with mesenchymal, classic, or neural tumours. The clinical 
usefulness of these novel classifiers is currently being tested in prospective cohort studies. 
 
 
Molecular classification of other primary brain tumours 
 
Ependymal tumours 
Ependymomas remain a domain for surgical and radiooncological treatment approaches whereas 
pharmacological strategies have remained largely disappointing, notably in adults.59 Although there 
has been significant progress in the molecular characterization of these tumours as well,60 this has not 
resulted in the definition of promising new molecular targets for intervention yet. However, it has 
become evident that there is considerable heterogeneity within this group of tumours as well, and 
based on the fact that especially distinguishing between WHO grade II and grade III might very 
challenging from a neuropathology perspective, approaches to molecularly subclassify this disease 
based on published literature are currently being assessed.61,62 For example, three prognostically 
relevant molecular subgroups of intracranial ependymomas have been proposed on the basis of DNA 
copy number changes: group 1 tumours have a favourable prognosis and carry gains on chromosomes 
9, 15q and 18 or loss of chromosome 6; group 2 tumours have an intermediate prognosis and largely 
balanced genomic profiles; group 3 tumours have a poor prognosis and are characterized by 1q gains 
or homozygous cyclin-dependent kinase inhibitor 2A (CDKN2A) deletions.60 Posterior fossa 
ependymomas have been reported to comprise three genetic subgroups characterized by (i) multiple 
concurrent DNA amplifications, (ii) gain of 1q, or (iii) a balanced karyotype. Moreover, 
ependymomas arising in different CNS regions, spinal, infratentorial or supratentorial, showed distinct 
mRNA expression signatures.63 More recent data suggest two distinct subgroups of posterior fossa 
ependymomas based on gene expression profiles: group A tumours with poor prognosis with frequent 
relapse and metastatic seeding are preferentially found in younger patients and more common in 
males. These are typically located in lateral parts of the 4th ventricle and carry mostly balanced 
genomes with frequent gain of 1q and loss of 22. Group B tumours show a more favourable prognosis 
 15 
and are genetically more unstable. These tumours are more prevalent in adults and located in the 
midline.64 From a diagnostic perspective it is interesting that these two posterior fossa ependymoma 
subgroups may be distinguished immunohistochemically, with group A tumours expressing LAMA2 
but not NELL2, while group B tumours show the opposite staining pattern.64.65 
 
Medulloblastoma 
Medulloblastoma is the most common malignant pediatric brain tumour, but may also occur in 
younger adults. More than any other brain tumour, medulloblastoma has become paradigmatic for the 
power of modern high throughput technology to allow subclassification and assignment to putative 
oncogenic pathways presumably reflecting different cells of origin or stages of neural development. 
Current approaches define four subgroups which, however, may be further subclassified: wingless 
(WNT), sonic hedgehog (SHH), group 3, and group 4, each characterized by differential expression 
profiles and characteristic patterns of age of onset, localization and outcome.66-69 Most importantly, the 
pediatric neurooncology community came up with a consensus paper supported by leading groups 
across the world agreeing to this classification approach.70 An immediate clinical consequence of this 
ground-breaking work has been that most new studies in North America and Europe account for the 
fact that WNT-driven medulloblastoma patients have an excellent overall survival with current therapy 
regimens, so it is now being tested whether it is safe to reduce the dose of RT for these patients. The 
first clinical experience with the smoothened inhibitor vismodegib as a targeted approach to 
medulloblastoma demonstrated a dramatic, albeit short-lived response.71 However, larger studies on 
less-heavily pre-treated patients are forthcoming using either vismodegib or LDE-225 and at first 
glance show promising results in patients whose tumours carry a SHH signature. A French-led 
European trial (MEVITEM, www.clinicaltrials.gov NCT#01601184) compares temozolomide alone 
versus temozolomide plus vismodegib in adult patients with recurrent medulloblastoma with SHH 
signature. Other approaches for the implementation of targeted therapeutic approaches into the 
pediatric and adult medulloblastoma clinical trial portfolio based on novel molecular classifiers are 
ongoing.  
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Meningioma 
Meningiomas are the most common tumors among all primary brain tumours. Although they are 
histologically benign most often (>90%) and histological subgroups have little clinical significance, a 
minority of meningiomas shows histological features of atypia, including most notably elevated 
mitotic activity or brain-infiltrative growth patterns. These atypical meningiomas correspond to WHO 
grade II and are associated with a high likelihood of local recurrence even after macroscopically 
complete resection. The rare anaplastic meningiomas (WHO grade III) are fast growing tumours with 
locally destructive growth that may even produce systemic metastases, mostly in lung, liver and bone 
(Webappendix). Thus, meningiomas represent a major challenge in neurological oncology. Surgery 
and RT are the principal therapeutic measures. Systemic pharmacotherapy has been notoriously 
unsuccessful, and molecular genetic profiling has not provided clues for targeted therapy approaches.72 
For decades there has been major interest in hormonal therapies for these tumours because estrogen 
receptors are expressed in approximately 10% and progesterone receptors in more than half of 
meningiomas, but therapeutic targeting of hormone receptors has not been successful. Somatostatin 
receptors may be expressed in 80-90% of meningiomas. Their assessment using 
immunohistochemistry or positron emission tomography (PET) has been proposed to select patients 
for treatment with somatostatin receptor agonists, but a recent prospective study exploring the activity 
of octreotide yielded disappointing results, with no responses and only 2 of 12 patients with prolonged 
stable disease.73 Genomic profiling has revealed inactivation of the tumour suppressor gene NF2 on 
22q in about 50% of meningiomas, including the majority of transitional, fibroblastic, atypical and 
anaplastic meningiomas. More recently, recurrent oncogenic mutations have been discovered in 
SMOH and AKT1 by deep sequencing approaches in NF2 wildtype tumours including special 
histological subtypes like the secretory meningioma.74 Further, genome-wide analyses of NF2-
wildtype meningiomas do not only point towards different genetic meningioma entities, but also 
revealed potential novel targets for intervention. Almost 25% of the meningiomas showed partly 
recurrent mutations in TNF receptor-associated factor (TRAF) 7, a protein involved in signalling 
processes of differentiation and apoptosis. SMOH mutations, which activate Hedgehog signalling, 
were identified in ~5% of NF2 wildtype meningiomas. These tumours, which were mainly of WHO 
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grade I, usually showed stable genomes, whereas atypical or anaplastic meningiomas often carried 
NF2 mutations, unstable genomes and demonstrated a predominantly hemispheric localization.75,76 
 
 
Outlook 
 
Tremendous progress has been made in the molecular classification of primary brain tumours. In the 
case of MGMT promoter methylation in glioblastoma in the elderly and 1p/19q co-deletions in 
anaplastic oligodendroglial tumours, molecular markers determine clinical decision making as of 
2012, based on few practice-changing academic trials.13,14,24,25 Depending on the outcome of ongoing 
phase II and III trials of novel targeted agents in newly diagnosed and recurrent glioblastoma, 
biomarkers to predict resistance or sensitivity to angiogenesis inhibition will move into focus, both in 
tumour tissue and in peripheral blood. In medulloblastoma, molecular subclassification is now used 
for selecting targeted agents depending on the dominant oncogenic pathway. Meanwhile, high-
throughput analyses at genetic, epigenetic and expression levels have demonstrated their value in 
classifying brain tumours and prognosticating outcome. These techniques may soon become more 
widely available, easier to standardise and less subject to bias, than single marker assessments, e.g., 
current ways of determining the MGMT status, and may soon become more cost-effective, too. 
Accordingly, we predict that the current histology-dominated diagnostic assessment of brain tumours 
will be increasingly supplemented by molecular diagnostic tests, which eventually may be gradually 
replaced by high throughput profiling techniques, including array-based approaches and next-
generation sequencing. This progress in molecular diagnostics will help to improve the precision of 
histological diagnoses, to select appropriate therapeutic measures, and to enrich patient populations for 
clinical trials.  
Yet, it is also important to realize that array-based approaches will not completely supplant targeted 
analyses. There are still instances where diagnoses are being rendered on miniscule portions of tissue 
obtained by biopsy or from the very edge of infiltrating gliomas where the nature of the lesion, tumour 
or not, is uncertain, and high-throughput techniques might not be as helpful or simply cannot be 
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applied due to limited tissue availability. 
In addition to the complex interdisciplinary dialogue required for optimized clinical decision making, 
the technical challenges associated with assessing molecular markers in brain tumour patients further 
support the call for centralized care of patients with relatively rare tumours, for whom an increasing 
repertoire of novel treatment options is currently being made available. 
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Figure legends 
 
Figure 1. Biomarker-based approach to anaplastic glioma  
Red: new standard practice, blue: to be confirmed: italics: alternative options. 
 
Figure 2. Biomarker-based approach to glioblastoma 
Red: new standard practice, italics: alternative options. 
 
Table 1. Molecular markers in gliomas: biological role, assessment, and clinical value. 
 
 IDH1/2 mutation 1p/19q co-deletion MGMT promoter 
methylation 
EGFRvIII 
rearrangement 
BRAF 
duplication / 
fusion 
BRAF activating 
point mutation 
       
Biological consequence Increased levels of 2-
hydroxyglutarate, link to 
G-CIMP phenotype 
Unclear, candidate 
genes CIC and 
FUBP1 under 
investigation 
Reduced DNA 
repair, association 
with G-CIMP 
phenotype in 
IDH1/2-mutant 
tumors 
Ligand-independent 
pathway activation 
MAPK pathway 
activation 
MAPK pathway 
activation 
       
Methods of assessment Immunohistochemistry 
for IDH1-R132H, 
(pyro)sequencing 
FISH, microsatellite 
analysis for loss of 
heterozygosity 
MSP, MS or 
bisulfite 
(pyro)sequencing 
RT-PCR, 
immunohistochemistry, 
MLPA 
FISH, RT-PCR Immunohistochemistry 
for BRAF-V600E, 
(pyro)sequencing 
       
Incidence       
Pilocytic astrocytoma 0% 0% <10% 0% 50-70% 10%  
Pleomorphic 
xanthoastrocytoma 
0% 0% 10-20% 0% rare 60-70% 
Diffuse astrocytoma 70-80% 15% 40-50% 0% rare rare 
Oligodendroglioma/ 
oligoastrocytoma 
70-80% 30-60% 60-80% 0% rare rare 
Anaplastic astrocytoma 50-70% 15% 50% 0% rare rare 
Anaplastic 
oligodendroglioma/ 
oligoastrocytoma 
50-80% 50-80% 70% 0% rare rare 
Glioblastoma 5-10% <5% 35% 25-30% rare 3-5% 
       
Diagnostic role Important, see above, 
differential diagnosis 
between diffuse glioma 
and gliosis 
Strong association 
with oligodendroglial 
morphology, 
differential diagnosis 
of brain tumors with 
clear cells 
None Strong association with 
glioblastoma 
Yes, see above Yes, see above 
Prognostic role Positive across 
histologies 
Favorable for 
oligodendroglial 
tumors treated with 
RT or alkylating agent 
chemotherapy or both 
Prognostic for 
anaplastic glioma 
patients (? with IDH 
mutations) treated 
with RT or 
alkylating agents 
Negative prognostic 
factor, reduced long-
term survival 
unclear unclear 
Predictive role Absence of mutation 
suggests predictive role 
for MGMT promoter 
methylation 
Patients with 1p/19-
codeleted (anaplastic) 
oligodendrogliomas 
should not be treated 
with RT alone, but 
alkylating agents ± RT 
Predictive for 
glioblastoma (? 
without IDH 
mutations) treated 
with alkylating 
agents, should be 
tested in elderly 
glioblastoma 
patients 
Possible biomarker for 
vaccination 
Possible 
biomarker for 
targeted therapy 
Possible biomarker for 
targeted therapy 
       
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Outcome by 1p/19q codeletion status in the anaplastic oligodendroglioma trials.13,14 
 
 EORTC 26951 
(n=368) 
  RTOG 9402 
(n=291) 
  
       
 RT RT→PCV  RT PCV→RT  
All patients       
Progression-free survival 
(years) 
1.1 2.0 HR=0.66 
95% CI 0.52-0.83 
no data in 2013 
update 
no data in 2013 
update 
 
Overall survival (years) 2.5 3.5 HR=0.75 
95% CI 0.6-0.95 
4.7 4.6 HR=0.79 
95% CI 0.6-1.04 
       
Patients with 1p/19q-
codeleted tumors 
      
Progression-free survival 
(years) 
4.2 13.1 HR=0.42 
95% CI 0.24-0.74 
2.9 8.4 HR=0.47 
95% CI 0.3-0.72 
Overall survival (years) 9.3 Not reached HR=0.56 
95% CI 0.31-1.03 
7.3 14.7 HR=0.59 
95% CI 0.37-0.95 
       
Patients with 1p/19q-non-
codeleted tumors 
      
Progression-free survival 
(years) 
0.7 1.2 0.73 
95% CI 0.56-0.97 
1 1.2 HR=0.81 
95% CI 56-116 
Overall survival (years) 1.8 2.1 HR=0.83 
95% CI 0.62-1.1 
2.7 2.6 HR=0.85 
95% CI 0.58-1.23 
 
 
 
 
 
 
 
Table 3. Outcome by MGMT promoter methylation status in the elderly glioblastoma (anaplastic astrocytoma) trials.24,25 
 
 NOA-081   Nordic trial    
        
 RT 30 x 2 Gy 
(n=178) 
TMZ 7/7 
(n=195) 
 RT 30 x 2 Gy 
(n=100) 
RT 10 x 3.4 Gy 
(n=123) 
TMZ 5/28 
(n=119) 
 
All patients        
Progression-free survival 
(months) 
4.7 3.3 HR=1.15 
95% CI 0.92-1.43 
p non-
inferiority=0.043 
 
 not reported   
Overall survival (months) 9.6 8.6 HR=1.09 
95% CI 0.84-1.42 
p non-
inferiority=0.033 
6 7.5 8.3 3TMZ: 
HR=0.70 
95% CI 0.52-0.93 
p=0.01 
3Hypofractionated RT: 
HR=0.85 
95% CI 0.64-1.12 
p=0.24 
        
Patients with MGMT 
promoter-methylated tumours 
       
Progression-free survival 
(months) 
4.6 8.4 HR=0.53 
95% CI 0.33–0.86 
p=0.01 
 not reported   
Overall survival (months) 9.6 not reached HR=0.69 
95% CI 0.35–1.16 
p=0.14 
 8.22 9.7 HR=0.64 
95% CI 0.39-1.04 
        
Patients with MGMT 
promoter-unmethylated 
tumours 
       
Progression-free survival 
(months) 
4.6 3.3 HR=1.95 
95% CI 1.41–2.69 
p=0.01 
 not reported   
Overall survival (months) 10.4 7 HR=1.34 
95% CI 0.92–1.95 
p= 0.13 
 71 6.8 HR=1.16 
95% CI 0.78-1.72 
 
1comprised 11% anaplastic astrocytoma 
2both RT groups pooled 
3comparison to standard RT (30 x 2 Gy) 
4TMZ relative to all patients receiving RT (with or without MGMT promoter methylation) which were pooled because they had a similar outcome in NOA-08 
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